SEC Form 4 · accession 0001209191-16-115079
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natalie McClure
Officer — SVP, Product Development
Period of report
Apr 18, 2016
Accepted (ET)
Apr 20, 2016 · 5:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 18, 2016 | M | 12,666 | $1.755 | A | 21,006 | D | |
| Common StockF1 | Apr 18, 2016 | S | 12,666 | $18.50 | D | 8,340 | D | |
| Common StockF1 | Apr 18, 2016 | M | 23,334 | $0.665 | A | 31,674 | D | |
| Common StockF1 | Apr 18, 2016 | S | 23,334 | $18.50 | D | 8,340 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.755 | Apr 18, 2016 | M | 12,666 | D | — | Mar 3, 2020 | Common Stock | 12,666 | 0 | D |
| Stock Option (Right to Buy)F3 | $0.665 | Apr 18, 2016 | M | 23,334 | D | — | Nov 16, 2021 | Common Stock | 23,334 | 16,666 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2This option is fully vested and exercisable.
- F3The Option shares shall vest as follows: one-fifth (1/5th) of the shares vest one year after June 30, 2011; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of June 30, 2011, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.